成人用ワクチンの世界市場

成人用ワクチンの世界市場は2030年までに225億米ドルに達する見込み

2024年に166億米ドルと推定される成人用ワクチンの世界市場は、2024～2030年の分析期間においてCAGR 5.2%で成長し、2030年には225億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである弱毒生ワクチンは、CAGR 6.5%を記録し、分析期間終了時には69億米ドルに達すると予測されます。不活化ワクチン分野の成長率は、分析期間中CAGR 5.9%と推定されます。

米国市場は推定45億米ドル、中国はCAGR9.6%で成長予測

米国の成人用ワクチン市場は、2024年には45億米ドルになると推定されます。世界第2位の経済大国である中国は、2030年までに48億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは9.6%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ2.1%と4.1%と予測されています。欧州では、ドイツがCAGR 3.1%で成長すると予測されています。

世界の成人用ワクチン市場- 主要動向と促進要因のまとめ

成人用ワクチンが生涯予防接種戦略と公衆衛生レジリエンスの中心になりつつある理由とは？

成人用ワクチンは、疾病予防、集団健康管理、ヘルスケアコスト抑制における重要なツールとして、ますます認知されるようになってきています。従来は小児期の予防接種が中心であったが、現在では成人向けのワクチンも、インフルエンザ、肺炎球菌感染症、帯状疱疹、肝炎、HPV、COVID-19をはじめとする幅広い感染症や、旅行関連や職業性曝露を対象としています。世界人口の高齢化と慢性疾患の蔓延に伴い、成人予防接種は罹患率、入院率、生産性の低下を抑える最前線の戦略として台頭してきています。

成人、特に高齢者や免疫不全者におけるワクチンで予防可能な疾病の負担に対する認識が高まり、予防接種政策やヘルスケア提供モデルが再構築されつつあります。政府、保険会社、雇用主は、予防医療の枠組みに成人用ワクチンを組み込む傾向を強めており、公衆衛生の回復力とシステムの持続可能性を高める上で生涯予防が重要であることを強調しています。

成人の予防接種ニーズを満たすために、ワクチン技術と供給モデルはどのように進化しているか？

リコンビナント技術、コンジュゲート製剤、mRNAプラットフォームなどの開発が、次世代成人用ワクチン開発の原動力となっています。これらの技術革新は、免疫原性の向上、予防効果の持続時間、幅広い株カバー率を提供し、呼吸器感染症、性感染症、媒介感染症のより効果的な予防を可能にしています。免疫老化を克服し、高齢者集団における有効性を向上させるために、アジュバントシステムや年齢をターゲットにした製剤が最適化されつつあります。

予防接種を提供する側では、薬局を拠点とした予防接種、移動診療所、職場予防接種プログラムの拡大により、アクセスの利便性と接種率が向上しています。ワクチンリマインダー、モバイルスケジューリング、予防接種記録などのデジタルヘルスツールは、アドヒアランスを向上させ、機会損失を減らしています。これらのモデルは、接種率格差の是正と成人の予防接種基盤の強化を目的とした官民パートナーシップによって、ますます支援されるようになってきています。

成人用ワクチンセグメントの成長を牽引する疾患領域と地域市場は？

インフルエンザ、COVID-19、肺炎球菌感染症を含む呼吸器疾患は、依然として成人用ワクチンの中で最も接種量の多いカテゴリーであり、HPV、帯状疱疹、肝炎がこれに続きます。ブースター接種、季節性予防接種、旅行関連リスクに対するワクチンに対する需要が特に強いです。成人を対象とした混合ワクチンの導入や、HPVや帯状疱疹の予防接種の適応拡大により、年齢層やリスクプロファイルを超えた需要がさらに多様化しています。

北米は、成熟した保険償還の枠組み、小売薬局の強力な参加、政府支援のワクチン接種プログラムにより、ワクチン摂取でリードしています。強固な公衆衛生インフラと人口動態の高齢化により、欧州がこれに続きます。アジア太平洋は、都市化、ヘルスケア・アクセスの改善、パンデミック後の予防接種に対する意識向上などを背景に急成長を遂げています。一方、ラテンアメリカとアフリカの一部では、WHOが支援するイニシアチブと地域疾病対策プログラムを通じて、成人ワクチンへのアクセスが拡大しています。

政策義務、健康公平性の目標、行動要因は市場開拓にどのような影響を与えているか？

各国の予防接種プログラムやCDC/WHOのガイドラインは、特に高齢者、妊婦、慢性疾患を持つ人に対する成人ワクチンの推奨を拡大しています。パンデミック期に行われたコールドチェーン能力、サーベイランス、データインフラへの投資は、より広範な成人予防接種キャンペーンを支援するために活用されています。しかし、アクセス、認知度、ワクチンに対する信頼性の格差は、特に十分なサービスを受けていない人々の予防接種率に影響を与え続けています。

利害関係者は、社会から疎外された人々のワクチン接種を改善するために、教育、文化的能力、経済的障壁を対象としています。行動科学はまた、信頼できる地域社会とのパートナーシップやニーズに合わせたメッセージングを活用して、ワクチン接種のためらいに対処する戦略にも情報を提供しています。このような取り組みは、世界の多様な状況において、成人予防接種プログラムの範囲と効果を最大化するために不可欠です。

成人用ワクチン市場の成長を促進する要因とは？

成人用ワクチン市場は、人口の高齢化、新たな感染症の脅威、医療制度改革によって予防医療の重要性が高まるにつれ、急速に拡大しています。主な成長促進要因としては、ワクチン・プラットフォームの技術的進歩、予防接種インフラへの投資の増加、より広範な政策義務化、成人病リスクに対する意識の高まりなどが挙げられます。業界の技術革新は、利便性と予防効果を高める複数病原体ワクチン、単回投与レジメン、スケーラブルな流通モデルの開発に集中しています。

今後、成人の予防接種を世界的に拡大するためには、技術革新、公平性、教育をいかに効果的に整合させるかによって、市場の勢いが左右されます。ヘルスケア制度が予防第一のモデルへと軸足を移す中、成人用ワクチンは、持続可能な集団全体の疾病対策に向けた最も戦略的なテコとなり得るだろうか。

セグメント

技術（弱毒生,不活化,サブユニット,トキソイド,混合,その他の技術）;ワクチンタイプ（1価ワクチン,多価ワクチン）;エンドユーザー（民間ヘルスケア企業,政府病院）

調査対象企業の例（合計 41注目）

• Altimmune, Inc.
• AstraZeneca plc
• Bavarian Nordic A/S
• Bharat Biotech International Ltd.
• Biological E. Limited
• CanSino Biologics Inc.
• CSL Limited
• Daiichi Sankyo Co., Ltd.
• Emergent BioSolutions Inc.
• GeneOne Life Science Inc.
• GlaxoSmithKline plc
• ImmunityBio, Inc.
• Inovio Pharmaceuticals, Inc.
• Johnson & Johnson
• Medigen Vaccine Biologics Corp.
• Meiji Seika Pharma Co., Ltd.
• Merck & Co., Inc.
• Moderna, Inc.
• Novavax, Inc.
• Pfizer Inc.

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、人為的な売上原価の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

Global Industry Analystsは、世界の主要なチーフ・エコノミスト（1万4,949人）、シンクタンク（62団体）、貿易・産業団体（171団体）の専門家の意見に熱心に従いながら、エコシステムへの影響を評価し、新たな市場の現実に対処しています。あらゆる主要国の専門家やエコノミストが、関税とそれが自国に与える影響についての意見を追跡調査しています。

Global Industry Analystsは、この混乱が今後2-3ヶ月で収束し、新しい世界秩序がより明確に確立されると予想しています。Global Industry Analystsは、これらの開発をリアルタイムで追跡しています。

2025年4月：交渉フェーズ

4月のリリースでは、世界市場全体に対する関税の影響を取り上げ、地域別の市場調整について紹介します。当社の予測は、過去のデータと進化する市場影響要因に基づいています。

2025年7月：最終関税リセット

お客様には、各国間で最終リセットが発表された後、7月に無料アップデート版をお届けします。最終アップデート版には、明確に定義された関税影響分析が組み込まれています。

相互および二国間貿易と関税の影響分析：

アメリカ <>中国<>メキシコ <>カナダ <>EU <>日本<>インド <>その他176カ国

業界をリードするエコノミスト：Global Industry Analystsの知識ベースは、国家、シンクタンク、貿易・産業団体、大企業、そして世界の計量経済状況におけるこの前例のないパラダイムシフトの影響を共有する領域の専門家など、最も影響力のあるチーフエコノミストの厳選されたグループを含む1万4,949人のエコノミストを追跡しています。我々の16,491以上のレポートのほとんどは、マイルストーンに基づくこの2段階のリリーススケジュールを取り入れています。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• スペイン
• ロシア
• その他欧州
• アジア太平洋
• オーストラリア
• インド
• 韓国
• その他アジア太平洋地域
• ラテンアメリカ
• アルゼンチン
• ブラジル
• メキシコ
• その他ラテンアメリカ
• 中東
• イラン
• イスラエル
• サウジアラビア
• アラブ首長国連邦
• その他中東
• アフリカ

第4章 競合

Global Adult Vaccines Market to Reach US$22.5 Billion by 2030

The global market for Adult Vaccines estimated at US$16.6 Billion in the year 2024, is expected to reach US$22.5 Billion by 2030, growing at a CAGR of 5.2% over the analysis period 2024-2030. Live Attenuated Vaccines, one of the segments analyzed in the report, is expected to record a 6.5% CAGR and reach US$6.9 Billion by the end of the analysis period. Growth in the Inactivated Vaccines segment is estimated at 5.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$4.5 Billion While China is Forecast to Grow at 9.6% CAGR

The Adult Vaccines market in the U.S. is estimated at US$4.5 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$4.8 Billion by the year 2030 trailing a CAGR of 9.6% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.1% and 4.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.1% CAGR.

Global Adult Vaccines Market - Key Trends & Drivers Summarized

Why Are Adult Vaccines Becoming Central to Lifelong Immunization Strategies and Public Health Resilience?

Adult vaccines are increasingly recognized as critical tools in disease prevention, population health management, and healthcare cost containment. While traditionally associated with childhood immunization, vaccines for adults now target a wide range of infectious diseases-including influenza, pneumococcal disease, shingles, hepatitis, HPV, and COVID-19-as well as travel-related and occupational exposures. As global populations age and chronic conditions become more prevalent, adult immunization is emerging as a frontline strategy to reduce morbidity, hospitalization, and productivity loss.

Growing recognition of vaccine-preventable disease burdens among adults, particularly the elderly and immunocompromised, is reshaping immunization policies and healthcare delivery models. Governments, insurers, and employers are increasingly integrating adult vaccines into preventive care frameworks, emphasizing the importance of lifelong protection in enhancing public health resilience and system sustainability.

How Are Vaccine Technologies and Delivery Models Evolving to Meet Adult Immunization Needs?

Advancements in recombinant technologies, conjugate formulations, and mRNA platforms are driving next-generation adult vaccine development. These innovations offer improved immunogenicity, longer-lasting protection, and broader strain coverage, enabling more effective prevention of respiratory, sexually transmitted, and vector-borne infections. Adjuvant systems and age-targeted formulations are being optimized to overcome immunosenescence and improve efficacy in older populations.

On the delivery side, expansion of pharmacy-based vaccination, mobile clinics, and workplace immunization programs is improving accessibility and uptake. Digital health tools-such as vaccine reminders, mobile scheduling, and immunization records-are enhancing adherence and reducing missed opportunities. These models are increasingly supported by public-private partnerships aimed at closing coverage gaps and strengthening immunization infrastructure for adults.

Which Disease Areas and Regional Markets Are Driving Growth in the Adult Vaccines Segment?

Respiratory diseases, including influenza, COVID-19, and pneumococcal infections, remain the highest-volume adult vaccine categories, followed by HPV, shingles, and hepatitis. Demand is particularly strong for booster doses, seasonal immunizations, and vaccines for travel-related risks. The introduction of adult-targeted combination vaccines and expanded indications for HPV and shingles immunization are further diversifying demand across age groups and risk profiles.

North America leads in vaccine uptake due to mature reimbursement frameworks, strong retail pharmacy participation, and government-supported vaccination programs. Europe follows with robust public health infrastructure and aging demographics. Asia-Pacific is experiencing rapid growth, driven by urbanization, improved healthcare access, and post-pandemic immunization awareness. Meanwhile, Latin America and parts of Africa are expanding adult vaccine access through WHO-backed initiatives and regional disease control programs.

How Are Policy Mandates, Health Equity Goals, and Behavioral Factors Influencing Market Development?

National immunization programs and CDC/WHO guidelines are expanding adult vaccine recommendations, particularly for older adults, pregnant women, and individuals with chronic illnesses. Pandemic-era investments in cold chain capacity, surveillance, and data infrastructure are being leveraged to support broader adult immunization campaigns. However, disparities in access, awareness, and vaccine confidence continue to impact uptake, particularly in underserved populations.

Health equity is becoming a priority, with stakeholders targeting education, cultural competency, and financial barriers to improve vaccine access for marginalized groups. Behavioral science is also informing strategies to address vaccine hesitancy, leveraging trusted community partnerships and tailored messaging. These efforts are essential in maximizing the reach and impact of adult immunization programs in diverse global contexts.

What Are the Factors Driving Growth in the Adult Vaccines Market?

The adult vaccines market is expanding rapidly as aging populations, emerging infectious threats, and health system reforms elevate the importance of preventive care. Key growth drivers include technological advances in vaccine platforms, increased investment in immunization infrastructure, broader policy mandates, and growing awareness of adult disease risks. Industry innovation is focused on developing multi-pathogen vaccines, single-dose regimens, and scalable distribution models that enhance both convenience and protection.

Looking forward, market momentum will depend on how effectively stakeholders align innovation, equity, and education in scaling adult immunization worldwide. As healthcare systems pivot toward prevention-first models, could adult vaccines become the most strategic lever for sustainable, population-wide disease control?

SCOPE OF STUDY:

The report analyzes the Adult Vaccines market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Technology (Live Attenuated, Inactivated, Subunit, Toxoid, Conjugate, Other Technologies); Vaccine Type (Monovalent Vaccine, Multivalent Vaccine); End-Use (Private Healthcare Firms, Government Hospitals)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 41 Featured) -

• Altimmune, Inc.
• AstraZeneca plc
• Bavarian Nordic A/S
• Bharat Biotech International Ltd.
• Biological E. Limited
• CanSino Biologics Inc.
• CSL Limited
• Daiichi Sankyo Co., Ltd.
• Emergent BioSolutions Inc.
• GeneOne Life Science Inc.
• GlaxoSmithKline plc
• ImmunityBio, Inc.
• Inovio Pharmaceuticals, Inc.
• Johnson & Johnson
• Medigen Vaccine Biologics Corp.
• Meiji Seika Pharma Co., Ltd.
• Merck & Co., Inc.
• Moderna, Inc.
• Novavax, Inc.
• Pfizer Inc.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Adult Vaccines - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Growing Awareness of Vaccine-Preventable Diseases Throws the Spotlight on Adult Immunization Uptake
  • Rising Aging Population and Comorbidities Spur Demand for Influenza, Pneumococcal, and Shingles Vaccines
  • Expanding Travel and Migration Trends Strengthen the Business Case for Adult Travel Immunizations
  • Increased Employer-Sponsored Wellness Programs Drive Vaccination in Working-Age Adults
  • Wider Availability of Combination Vaccines Supports Uptake Through Simplified Schedules
  • Proliferation of Retail and Pharmacy-Based Vaccination Points Bodes Well for Adult Vaccine Accessibility
  • Growing Focus on Preventive Healthcare in Emerging Economies Fuels Market Expansion
  • Success of COVID-19 Vaccine Campaigns Sets the Stage for Sustained Public Health Investment in Adult Immunization
  • Rise in HPV and Hepatitis B Cases Among Adults Generates New Target Populations
  • Digital Immunization Records and Reminders Improve Compliance with Booster Schedules
  • Expansion of National Immunization Guidelines to Include Adults Enhances Institutional Backing for Market Growth
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Adult Vaccines Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Adult Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Adult Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 4: World 15-Year Perspective for Adult Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Live Attenuated by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Live Attenuated by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 7: World 15-Year Perspective for Live Attenuated by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Inactivated by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Inactivated by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 10: World 15-Year Perspective for Inactivated by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Subunit by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Subunit by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 13: World 15-Year Perspective for Subunit by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Toxoid by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Toxoid by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 16: World 15-Year Perspective for Toxoid by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Conjugate by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Conjugate by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 19: World 15-Year Perspective for Conjugate by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Other Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Other Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 22: World 15-Year Perspective for Other Technologies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Government Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Government Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 25: World 15-Year Perspective for Government Hospitals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Private Healthcare Firms by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Private Healthcare Firms by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 28: World 15-Year Perspective for Private Healthcare Firms by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Monovalent Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Monovalent Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 31: World 15-Year Perspective for Monovalent Vaccine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 32: World Recent Past, Current & Future Analysis for Multivalent Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 33: World Historic Review for Multivalent Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 34: World 15-Year Perspective for Multivalent Vaccine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Adult Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 35: USA Recent Past, Current & Future Analysis for Adult Vaccines by Technology - Live Attenuated, Inactivated, Subunit, Toxoid, Conjugate and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 36: USA Historic Review for Adult Vaccines by Technology - Live Attenuated, Inactivated, Subunit, Toxoid, Conjugate and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 37: USA 15-Year Perspective for Adult Vaccines by Technology - Percentage Breakdown of Value Sales for Live Attenuated, Inactivated, Subunit, Toxoid, Conjugate and Other Technologies for the Years 2015, 2025 & 2030
  • TABLE 38: USA Recent Past, Current & Future Analysis for Adult Vaccines by End-Use - Government Hospitals and Private Healthcare Firms - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 39: USA Historic Review for Adult Vaccines by End-Use - Government Hospitals and Private Healthcare Firms Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 40: USA 15-Year Perspective for Adult Vaccines by End-Use - Percentage Breakdown of Value Sales for Government Hospitals and Private Healthcare Firms for the Years 2015, 2025 & 2030
  • TABLE 41: USA Recent Past, Current & Future Analysis for Adult Vaccines by Vaccine Type - Monovalent Vaccine and Multivalent Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 42: USA Historic Review for Adult Vaccines by Vaccine Type - Monovalent Vaccine and Multivalent Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 43: USA 15-Year Perspective for Adult Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Monovalent Vaccine and Multivalent Vaccine for the Years 2015, 2025 & 2030
• CANADA
  • TABLE 44: Canada Recent Past, Current & Future Analysis for Adult Vaccines by Technology - Live Attenuated, Inactivated, Subunit, Toxoid, Conjugate and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 45: Canada Historic Review for Adult Vaccines by Technology - Live Attenuated, Inactivated, Subunit, Toxoid, Conjugate and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 46: Canada 15-Year Perspective for Adult Vaccines by Technology - Percentage Breakdown of Value Sales for Live Attenuated, Inactivated, Subunit, Toxoid, Conjugate and Other Technologies for the Years 2015, 2025 & 2030
  • TABLE 47: Canada Recent Past, Current & Future Analysis for Adult Vaccines by End-Use - Government Hospitals and Private Healthcare Firms - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 48: Canada Historic Review for Adult Vaccines by End-Use - Government Hospitals and Private Healthcare Firms Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 49: Canada 15-Year Perspective for Adult Vaccines by End-Use - Percentage Breakdown of Value Sales for Government Hospitals and Private Healthcare Firms for the Years 2015, 2025 & 2030
  • TABLE 50: Canada Recent Past, Current & Future Analysis for Adult Vaccines by Vaccine Type - Monovalent Vaccine and Multivalent Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 51: Canada Historic Review for Adult Vaccines by Vaccine Type - Monovalent Vaccine and Multivalent Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 52: Canada 15-Year Perspective for Adult Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Monovalent Vaccine and Multivalent Vaccine for the Years 2015, 2025 & 2030
• JAPAN
  • Adult Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 53: Japan Recent Past, Current & Future Analysis for Adult Vaccines by Technology - Live Attenuated, Inactivated, Subunit, Toxoid, Conjugate and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 54: Japan Historic Review for Adult Vaccines by Technology - Live Attenuated, Inactivated, Subunit, Toxoid, Conjugate and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 55: Japan 15-Year Perspective for Adult Vaccines by Technology - Percentage Breakdown of Value Sales for Live Attenuated, Inactivated, Subunit, Toxoid, Conjugate and Other Technologies for the Years 2015, 2025 & 2030
  • TABLE 56: Japan Recent Past, Current & Future Analysis for Adult Vaccines by End-Use - Government Hospitals and Private Healthcare Firms - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 57: Japan Historic Review for Adult Vaccines by End-Use - Government Hospitals and Private Healthcare Firms Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 58: Japan 15-Year Perspective for Adult Vaccines by End-Use - Percentage Breakdown of Value Sales for Government Hospitals and Private Healthcare Firms for the Years 2015, 2025 & 2030
  • TABLE 59: Japan Recent Past, Current & Future Analysis for Adult Vaccines by Vaccine Type - Monovalent Vaccine and Multivalent Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 60: Japan Historic Review for Adult Vaccines by Vaccine Type - Monovalent Vaccine and Multivalent Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 61: Japan 15-Year Perspective for Adult Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Monovalent Vaccine and Multivalent Vaccine for the Years 2015, 2025 & 2030
• CHINA
  • Adult Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 62: China Recent Past, Current & Future Analysis for Adult Vaccines by Technology - Live Attenuated, Inactivated, Subunit, Toxoid, Conjugate and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 63: China Historic Review for Adult Vaccines by Technology - Live Attenuated, Inactivated, Subunit, Toxoid, Conjugate and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 64: China 15-Year Perspective for Adult Vaccines by Technology - Percentage Breakdown of Value Sales for Live Attenuated, Inactivated, Subunit, Toxoid, Conjugate and Other Technologies for the Years 2015, 2025 & 2030
  • TABLE 65: China Recent Past, Current & Future Analysis for Adult Vaccines by End-Use - Government Hospitals and Private Healthcare Firms - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 66: China Historic Review for Adult Vaccines by End-Use - Government Hospitals and Private Healthcare Firms Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 67: China 15-Year Perspective for Adult Vaccines by End-Use - Percentage Breakdown of Value Sales for Government Hospitals and Private Healthcare Firms for the Years 2015, 2025 & 2030
  • TABLE 68: China Recent Past, Current & Future Analysis for Adult Vaccines by Vaccine Type - Monovalent Vaccine and Multivalent Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 69: China Historic Review for Adult Vaccines by Vaccine Type - Monovalent Vaccine and Multivalent Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 70: China 15-Year Perspective for Adult Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Monovalent Vaccine and Multivalent Vaccine for the Years 2015, 2025 & 2030
• EUROPE
  • Adult Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 71: Europe Recent Past, Current & Future Analysis for Adult Vaccines by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 72: Europe Historic Review for Adult Vaccines by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 73: Europe 15-Year Perspective for Adult Vaccines by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
  • TABLE 74: Europe Recent Past, Current & Future Analysis for Adult Vaccines by Technology - Live Attenuated, Inactivated, Subunit, Toxoid, Conjugate and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 75: Europe Historic Review for Adult Vaccines by Technology - Live Attenuated, Inactivated, Subunit, Toxoid, Conjugate and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 76: Europe 15-Year Perspective for Adult Vaccines by Technology - Percentage Breakdown of Value Sales for Live Attenuated, Inactivated, Subunit, Toxoid, Conjugate and Other Technologies for the Years 2015, 2025 & 2030
  • TABLE 77: Europe Recent Past, Current & Future Analysis for Adult Vaccines by End-Use - Government Hospitals and Private Healthcare Firms - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 78: Europe Historic Review for Adult Vaccines by End-Use - Government Hospitals and Private Healthcare Firms Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 79: Europe 15-Year Perspective for Adult Vaccines by End-Use - Percentage Breakdown of Value Sales for Government Hospitals and Private Healthcare Firms for the Years 2015, 2025 & 2030
  • TABLE 80: Europe Recent Past, Current & Future Analysis for Adult Vaccines by Vaccine Type - Monovalent Vaccine and Multivalent Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 81: Europe Historic Review for Adult Vaccines by Vaccine Type - Monovalent Vaccine and Multivalent Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 82: Europe 15-Year Perspective for Adult Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Monovalent Vaccine and Multivalent Vaccine for the Years 2015, 2025 & 2030
• FRANCE
  • Adult Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 83: France Recent Past, Current & Future Analysis for Adult Vaccines by Technology - Live Attenuated, Inactivated, Subunit, Toxoid, Conjugate and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 84: France Historic Review for Adult Vaccines by Technology - Live Attenuated, Inactivated, Subunit, Toxoid, Conjugate and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 85: France 15-Year Perspective for Adult Vaccines by Technology - Percentage Breakdown of Value Sales for Live Attenuated, Inactivated, Subunit, Toxoid, Conjugate and Other Technologies for the Years 2015, 2025 & 2030
  • TABLE 86: France Recent Past, Current & Future Analysis for Adult Vaccines by End-Use - Government Hospitals and Private Healthcare Firms - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 87: France Historic Review for Adult Vaccines by End-Use - Government Hospitals and Private Healthcare Firms Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 88: France 15-Year Perspective for Adult Vaccines by End-Use - Percentage Breakdown of Value Sales for Government Hospitals and Private Healthcare Firms for the Years 2015, 2025 & 2030
  • TABLE 89: France Recent Past, Current & Future Analysis for Adult Vaccines by Vaccine Type - Monovalent Vaccine and Multivalent Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 90: France Historic Review for Adult Vaccines by Vaccine Type - Monovalent Vaccine and Multivalent Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 91: France 15-Year Perspective for Adult Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Monovalent Vaccine and Multivalent Vaccine for the Years 2015, 2025 & 2030
• GERMANY
  • Adult Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 92: Germany Recent Past, Current & Future Analysis for Adult Vaccines by Technology - Live Attenuated, Inactivated, Subunit, Toxoid, Conjugate and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 93: Germany Historic Review for Adult Vaccines by Technology - Live Attenuated, Inactivated, Subunit, Toxoid, Conjugate and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 94: Germany 15-Year Perspective for Adult Vaccines by Technology - Percentage Breakdown of Value Sales for Live Attenuated, Inactivated, Subunit, Toxoid, Conjugate and Other Technologies for the Years 2015, 2025 & 2030
  • TABLE 95: Germany Recent Past, Current & Future Analysis for Adult Vaccines by End-Use - Government Hospitals and Private Healthcare Firms - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 96: Germany Historic Review for Adult Vaccines by End-Use - Government Hospitals and Private Healthcare Firms Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 97: Germany 15-Year Perspective for Adult Vaccines by End-Use - Percentage Breakdown of Value Sales for Government Hospitals and Private Healthcare Firms for the Years 2015, 2025 & 2030
  • TABLE 98: Germany Recent Past, Current & Future Analysis for Adult Vaccines by Vaccine Type - Monovalent Vaccine and Multivalent Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 99: Germany Historic Review for Adult Vaccines by Vaccine Type - Monovalent Vaccine and Multivalent Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 100: Germany 15-Year Perspective for Adult Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Monovalent Vaccine and Multivalent Vaccine for the Years 2015, 2025 & 2030
• ITALY
  • TABLE 101: Italy Recent Past, Current & Future Analysis for Adult Vaccines by Technology - Live Attenuated, Inactivated, Subunit, Toxoid, Conjugate and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 102: Italy Historic Review for Adult Vaccines by Technology - Live Attenuated, Inactivated, Subunit, Toxoid, Conjugate and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 103: Italy 15-Year Perspective for Adult Vaccines by Technology - Percentage Breakdown of Value Sales for Live Attenuated, Inactivated, Subunit, Toxoid, Conjugate and Other Technologies for the Years 2015, 2025 & 2030
  • TABLE 104: Italy Recent Past, Current & Future Analysis for Adult Vaccines by End-Use - Government Hospitals and Private Healthcare Firms - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 105: Italy Historic Review for Adult Vaccines by End-Use - Government Hospitals and Private Healthcare Firms Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 106: Italy 15-Year Perspective for Adult Vaccines by End-Use - Percentage Breakdown of Value Sales for Government Hospitals and Private Healthcare Firms for the Years 2015, 2025 & 2030
  • TABLE 107: Italy Recent Past, Current & Future Analysis for Adult Vaccines by Vaccine Type - Monovalent Vaccine and Multivalent Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 108: Italy Historic Review for Adult Vaccines by Vaccine Type - Monovalent Vaccine and Multivalent Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 109: Italy 15-Year Perspective for Adult Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Monovalent Vaccine and Multivalent Vaccine for the Years 2015, 2025 & 2030
• UNITED KINGDOM
  • Adult Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 110: UK Recent Past, Current & Future Analysis for Adult Vaccines by Technology - Live Attenuated, Inactivated, Subunit, Toxoid, Conjugate and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 111: UK Historic Review for Adult Vaccines by Technology - Live Attenuated, Inactivated, Subunit, Toxoid, Conjugate and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 112: UK 15-Year Perspective for Adult Vaccines by Technology - Percentage Breakdown of Value Sales for Live Attenuated, Inactivated, Subunit, Toxoid, Conjugate and Other Technologies for the Years 2015, 2025 & 2030
  • TABLE 113: UK Recent Past, Current & Future Analysis for Adult Vaccines by End-Use - Government Hospitals and Private Healthcare Firms - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 114: UK Historic Review for Adult Vaccines by End-Use - Government Hospitals and Private Healthcare Firms Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 115: UK 15-Year Perspective for Adult Vaccines by End-Use - Percentage Breakdown of Value Sales for Government Hospitals and Private Healthcare Firms for the Years 2015, 2025 & 2030
  • TABLE 116: UK Recent Past, Current & Future Analysis for Adult Vaccines by Vaccine Type - Monovalent Vaccine and Multivalent Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 117: UK Historic Review for Adult Vaccines by Vaccine Type - Monovalent Vaccine and Multivalent Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 118: UK 15-Year Perspective for Adult Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Monovalent Vaccine and Multivalent Vaccine for the Years 2015, 2025 & 2030
• SPAIN
  • TABLE 119: Spain Recent Past, Current & Future Analysis for Adult Vaccines by Technology - Live Attenuated, Inactivated, Subunit, Toxoid, Conjugate and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 120: Spain Historic Review for Adult Vaccines by Technology - Live Attenuated, Inactivated, Subunit, Toxoid, Conjugate and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 121: Spain 15-Year Perspective for Adult Vaccines by Technology - Percentage Breakdown of Value Sales for Live Attenuated, Inactivated, Subunit, Toxoid, Conjugate and Other Technologies for the Years 2015, 2025 & 2030
  • TABLE 122: Spain Recent Past, Current & Future Analysis for Adult Vaccines by End-Use - Government Hospitals and Private Healthcare Firms - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 123: Spain Historic Review for Adult Vaccines by End-Use - Government Hospitals and Private Healthcare Firms Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 124: Spain 15-Year Perspective for Adult Vaccines by End-Use - Percentage Breakdown of Value Sales for Government Hospitals and Private Healthcare Firms for the Years 2015, 2025 & 2030
  • TABLE 125: Spain Recent Past, Current & Future Analysis for Adult Vaccines by Vaccine Type - Monovalent Vaccine and Multivalent Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 126: Spain Historic Review for Adult Vaccines by Vaccine Type - Monovalent Vaccine and Multivalent Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 127: Spain 15-Year Perspective for Adult Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Monovalent Vaccine and Multivalent Vaccine for the Years 2015, 2025 & 2030
• RUSSIA
  • TABLE 128: Russia Recent Past, Current & Future Analysis for Adult Vaccines by Technology - Live Attenuated, Inactivated, Subunit, Toxoid, Conjugate and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 129: Russia Historic Review for Adult Vaccines by Technology - Live Attenuated, Inactivated, Subunit, Toxoid, Conjugate and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 130: Russia 15-Year Perspective for Adult Vaccines by Technology - Percentage Breakdown of Value Sales for Live Attenuated, Inactivated, Subunit, Toxoid, Conjugate and Other Technologies for the Years 2015, 2025 & 2030
  • TABLE 131: Russia Recent Past, Current & Future Analysis for Adult Vaccines by End-Use - Government Hospitals and Private Healthcare Firms - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 132: Russia Historic Review for Adult Vaccines by End-Use - Government Hospitals and Private Healthcare Firms Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 133: Russia 15-Year Perspective for Adult Vaccines by End-Use - Percentage Breakdown of Value Sales for Government Hospitals and Private Healthcare Firms for the Years 2015, 2025 & 2030
  • TABLE 134: Russia Recent Past, Current & Future Analysis for Adult Vaccines by Vaccine Type - Monovalent Vaccine and Multivalent Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 135: Russia Historic Review for Adult Vaccines by Vaccine Type - Monovalent Vaccine and Multivalent Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 136: Russia 15-Year Perspective for Adult Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Monovalent Vaccine and Multivalent Vaccine for the Years 2015, 2025 & 2030
• REST OF EUROPE
  • TABLE 137: Rest of Europe Recent Past, Current & Future Analysis for Adult Vaccines by Technology - Live Attenuated, Inactivated, Subunit, Toxoid, Conjugate and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 138: Rest of Europe Historic Review for Adult Vaccines by Technology - Live Attenuated, Inactivated, Subunit, Toxoid, Conjugate and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 139: Rest of Europe 15-Year Perspective for Adult Vaccines by Technology - Percentage Breakdown of Value Sales for Live Attenuated, Inactivated, Subunit, Toxoid, Conjugate and Other Technologies for the Years 2015, 2025 & 2030
  • TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for Adult Vaccines by End-Use - Government Hospitals and Private Healthcare Firms - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 141: Rest of Europe Historic Review for Adult Vaccines by End-Use - Government Hospitals and Private Healthcare Firms Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 142: Rest of Europe 15-Year Perspective for Adult Vaccines by End-Use - Percentage Breakdown of Value Sales for Government Hospitals and Private Healthcare Firms for the Years 2015, 2025 & 2030
  • TABLE 143: Rest of Europe Recent Past, Current & Future Analysis for Adult Vaccines by Vaccine Type - Monovalent Vaccine and Multivalent Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 144: Rest of Europe Historic Review for Adult Vaccines by Vaccine Type - Monovalent Vaccine and Multivalent Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 145: Rest of Europe 15-Year Perspective for Adult Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Monovalent Vaccine and Multivalent Vaccine for the Years 2015, 2025 & 2030
• ASIA-PACIFIC
  • Adult Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 146: Asia-Pacific Recent Past, Current & Future Analysis for Adult Vaccines by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 147: Asia-Pacific Historic Review for Adult Vaccines by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 148: Asia-Pacific 15-Year Perspective for Adult Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
  • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Adult Vaccines by Technology - Live Attenuated, Inactivated, Subunit, Toxoid, Conjugate and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 150: Asia-Pacific Historic Review for Adult Vaccines by Technology - Live Attenuated, Inactivated, Subunit, Toxoid, Conjugate and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 151: Asia-Pacific 15-Year Perspective for Adult Vaccines by Technology - Percentage Breakdown of Value Sales for Live Attenuated, Inactivated, Subunit, Toxoid, Conjugate and Other Technologies for the Years 2015, 2025 & 2030
  • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Adult Vaccines by End-Use - Government Hospitals and Private Healthcare Firms - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 153: Asia-Pacific Historic Review for Adult Vaccines by End-Use - Government Hospitals and Private Healthcare Firms Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 154: Asia-Pacific 15-Year Perspective for Adult Vaccines by End-Use - Percentage Breakdown of Value Sales for Government Hospitals and Private Healthcare Firms for the Years 2015, 2025 & 2030
  • TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Adult Vaccines by Vaccine Type - Monovalent Vaccine and Multivalent Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 156: Asia-Pacific Historic Review for Adult Vaccines by Vaccine Type - Monovalent Vaccine and Multivalent Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 157: Asia-Pacific 15-Year Perspective for Adult Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Monovalent Vaccine and Multivalent Vaccine for the Years 2015, 2025 & 2030
• AUSTRALIA
  • Adult Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 158: Australia Recent Past, Current & Future Analysis for Adult Vaccines by Technology - Live Attenuated, Inactivated, Subunit, Toxoid, Conjugate and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 159: Australia Historic Review for Adult Vaccines by Technology - Live Attenuated, Inactivated, Subunit, Toxoid, Conjugate and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 160: Australia 15-Year Perspective for Adult Vaccines by Technology - Percentage Breakdown of Value Sales for Live Attenuated, Inactivated, Subunit, Toxoid, Conjugate and Other Technologies for the Years 2015, 2025 & 2030
  • TABLE 161: Australia Recent Past, Current & Future Analysis for Adult Vaccines by End-Use - Government Hospitals and Private Healthcare Firms - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 162: Australia Historic Review for Adult Vaccines by End-Use - Government Hospitals and Private Healthcare Firms Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 163: Australia 15-Year Perspective for Adult Vaccines by End-Use - Percentage Breakdown of Value Sales for Government Hospitals and Private Healthcare Firms for the Years 2015, 2025 & 2030
  • TABLE 164: Australia Recent Past, Current & Future Analysis for Adult Vaccines by Vaccine Type - Monovalent Vaccine and Multivalent Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 165: Australia Historic Review for Adult Vaccines by Vaccine Type - Monovalent Vaccine and Multivalent Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 166: Australia 15-Year Perspective for Adult Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Monovalent Vaccine and Multivalent Vaccine for the Years 2015, 2025 & 2030
• INDIA
  • Adult Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 167: India Recent Past, Current & Future Analysis for Adult Vaccines by Technology - Live Attenuated, Inactivated, Subunit, Toxoid, Conjugate and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 168: India Historic Review for Adult Vaccines by Technology - Live Attenuated, Inactivated, Subunit, Toxoid, Conjugate and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 169: India 15-Year Perspective for Adult Vaccines by Technology - Percentage Breakdown of Value Sales for Live Attenuated, Inactivated, Subunit, Toxoid, Conjugate and Other Technologies for the Years 2015, 2025 & 2030
  • TABLE 170: India Recent Past, Current & Future Analysis for Adult Vaccines by End-Use - Government Hospitals and Private Healthcare Firms - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 171: India Historic Review for Adult Vaccines by End-Use - Government Hospitals and Private Healthcare Firms Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 172: India 15-Year Perspective for Adult Vaccines by End-Use - Percentage Breakdown of Value Sales for Government Hospitals and Private Healthcare Firms for the Years 2015, 2025 & 2030
  • TABLE 173: India Recent Past, Current & Future Analysis for Adult Vaccines by Vaccine Type - Monovalent Vaccine and Multivalent Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 174: India Historic Review for Adult Vaccines by Vaccine Type - Monovalent Vaccine and Multivalent Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 175: India 15-Year Perspective for Adult Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Monovalent Vaccine and Multivalent Vaccine for the Years 2015, 2025 & 2030
• SOUTH KOREA
  • TABLE 176: South Korea Recent Past, Current & Future Analysis for Adult Vaccines by Technology - Live Attenuated, Inactivated, Subunit, Toxoid, Conjugate and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 177: South Korea Historic Review for Adult Vaccines by Technology - Live Attenuated, Inactivated, Subunit, Toxoid, Conjugate and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 178: South Korea 15-Year Perspective for Adult Vaccines by Technology - Percentage Breakdown of Value Sales for Live Attenuated, Inactivated, Subunit, Toxoid, Conjugate and Other Technologies for the Years 2015, 2025 & 2030
  • TABLE 179: South Korea Recent Past, Current & Future Analysis for Adult Vaccines by End-Use - Government Hospitals and Private Healthcare Firms - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 180: South Korea Historic Review for Adult Vaccines by End-Use - Government Hospitals and Private Healthcare Firms Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 181: South Korea 15-Year Perspective for Adult Vaccines by End-Use - Percentage Breakdown of Value Sales for Government Hospitals and Private Healthcare Firms for the Years 2015, 2025 & 2030
  • TABLE 182: South Korea Recent Past, Current & Future Analysis for Adult Vaccines by Vaccine Type - Monovalent Vaccine and Multivalent Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 183: South Korea Historic Review for Adult Vaccines by Vaccine Type - Monovalent Vaccine and Multivalent Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 184: South Korea 15-Year Perspective for Adult Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Monovalent Vaccine and Multivalent Vaccine for the Years 2015, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 185: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Adult Vaccines by Technology - Live Attenuated, Inactivated, Subunit, Toxoid, Conjugate and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 186: Rest of Asia-Pacific Historic Review for Adult Vaccines by Technology - Live Attenuated, Inactivated, Subunit, Toxoid, Conjugate and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 187: Rest of Asia-Pacific 15-Year Perspective for Adult Vaccines by Technology - Percentage Breakdown of Value Sales for Live Attenuated, Inactivated, Subunit, Toxoid, Conjugate and Other Technologies for the Years 2015, 2025 & 2030
  • TABLE 188: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Adult Vaccines by End-Use - Government Hospitals and Private Healthcare Firms - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 189: Rest of Asia-Pacific Historic Review for Adult Vaccines by End-Use - Government Hospitals and Private Healthcare Firms Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 190: Rest of Asia-Pacific 15-Year Perspective for Adult Vaccines by End-Use - Percentage Breakdown of Value Sales for Government Hospitals and Private Healthcare Firms for the Years 2015, 2025 & 2030
  • TABLE 191: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Adult Vaccines by Vaccine Type - Monovalent Vaccine and Multivalent Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 192: Rest of Asia-Pacific Historic Review for Adult Vaccines by Vaccine Type - Monovalent Vaccine and Multivalent Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 193: Rest of Asia-Pacific 15-Year Perspective for Adult Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Monovalent Vaccine and Multivalent Vaccine for the Years 2015, 2025 & 2030
• LATIN AMERICA
  • Adult Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 194: Latin America Recent Past, Current & Future Analysis for Adult Vaccines by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 195: Latin America Historic Review for Adult Vaccines by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 196: Latin America 15-Year Perspective for Adult Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
  • TABLE 197: Latin America Recent Past, Current & Future Analysis for Adult Vaccines by Technology - Live Attenuated, Inactivated, Subunit, Toxoid, Conjugate and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 198: Latin America Historic Review for Adult Vaccines by Technology - Live Attenuated, Inactivated, Subunit, Toxoid, Conjugate and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 199: Latin America 15-Year Perspective for Adult Vaccines by Technology - Percentage Breakdown of Value Sales for Live Attenuated, Inactivated, Subunit, Toxoid, Conjugate and Other Technologies for the Years 2015, 2025 & 2030
  • TABLE 200: Latin America Recent Past, Current & Future Analysis for Adult Vaccines by End-Use - Government Hospitals and Private Healthcare Firms - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 201: Latin America Historic Review for Adult Vaccines by End-Use - Government Hospitals and Private Healthcare Firms Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 202: Latin America 15-Year Perspective for Adult Vaccines by End-Use - Percentage Breakdown of Value Sales for Government Hospitals and Private Healthcare Firms for the Years 2015, 2025 & 2030
  • TABLE 203: Latin America Recent Past, Current & Future Analysis for Adult Vaccines by Vaccine Type - Monovalent Vaccine and Multivalent Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 204: Latin America Historic Review for Adult Vaccines by Vaccine Type - Monovalent Vaccine and Multivalent Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 205: Latin America 15-Year Perspective for Adult Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Monovalent Vaccine and Multivalent Vaccine for the Years 2015, 2025 & 2030
• ARGENTINA
  • TABLE 206: Argentina Recent Past, Current & Future Analysis for Adult Vaccines by Technology - Live Attenuated, Inactivated, Subunit, Toxoid, Conjugate and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Argentina Historic Review for Adult Vaccines by Technology - Live Attenuated, Inactivated, Subunit, Toxoid, Conjugate and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 208: Argentina 15-Year Perspective for Adult Vaccines by Technology - Percentage Breakdown of Value Sales for Live Attenuated, Inactivated, Subunit, Toxoid, Conjugate and Other Technologies for the Years 2015, 2025 & 2030
  • TABLE 209: Argentina Recent Past, Current & Future Analysis for Adult Vaccines by End-Use - Government Hospitals and Private Healthcare Firms - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 210: Argentina Historic Review for Adult Vaccines by End-Use - Government Hospitals and Private Healthcare Firms Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 211: Argentina 15-Year Perspective for Adult Vaccines by End-Use - Percentage Breakdown of Value Sales for Government Hospitals and Private Healthcare Firms for the Years 2015, 2025 & 2030
  • TABLE 212: Argentina Recent Past, Current & Future Analysis for Adult Vaccines by Vaccine Type - Monovalent Vaccine and Multivalent Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 213: Argentina Historic Review for Adult Vaccines by Vaccine Type - Monovalent Vaccine and Multivalent Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 214: Argentina 15-Year Perspective for Adult Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Monovalent Vaccine and Multivalent Vaccine for the Years 2015, 2025 & 2030
• BRAZIL
  • TABLE 215: Brazil Recent Past, Current & Future Analysis for Adult Vaccines by Technology - Live Attenuated, Inactivated, Subunit, Toxoid, Conjugate and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 216: Brazil Historic Review for Adult Vaccines by Technology - Live Attenuated, Inactivated, Subunit, Toxoid, Conjugate and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 217: Brazil 15-Year Perspective for Adult Vaccines by Technology - Percentage Breakdown of Value Sales for Live Attenuated, Inactivated, Subunit, Toxoid, Conjugate and Other Technologies for the Years 2015, 2025 & 2030
  • TABLE 218: Brazil Recent Past, Current & Future Analysis for Adult Vaccines by End-Use - Government Hospitals and Private Healthcare Firms - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 219: Brazil Historic Review for Adult Vaccines by End-Use - Government Hospitals and Private Healthcare Firms Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 220: Brazil 15-Year Perspective for Adult Vaccines by End-Use - Percentage Breakdown of Value Sales for Government Hospitals and Private Healthcare Firms for the Years 2015, 2025 & 2030
  • TABLE 221: Brazil Recent Past, Current & Future Analysis for Adult Vaccines by Vaccine Type - Monovalent Vaccine and Multivalent Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 222: Brazil Historic Review for Adult Vaccines by Vaccine Type - Monovalent Vaccine and Multivalent Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 223: Brazil 15-Year Perspective for Adult Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Monovalent Vaccine and Multivalent Vaccine for the Years 2015, 2025 & 2030
• MEXICO
  • TABLE 224: Mexico Recent Past, Current & Future Analysis for Adult Vaccines by Technology - Live Attenuated, Inactivated, Subunit, Toxoid, Conjugate and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 225: Mexico Historic Review for Adult Vaccines by Technology - Live Attenuated, Inactivated, Subunit, Toxoid, Conjugate and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 226: Mexico 15-Year Perspective for Adult Vaccines by Technology - Percentage Breakdown of Value Sales for Live Attenuated, Inactivated, Subunit, Toxoid, Conjugate and Other Technologies for the Years 2015, 2025 & 2030
  • TABLE 227: Mexico Recent Past, Current & Future Analysis for Adult Vaccines by End-Use - Government Hospitals and Private Healthcare Firms - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 228: Mexico Historic Review for Adult Vaccines by End-Use - Government Hospitals and Private Healthcare Firms Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 229: Mexico 15-Year Perspective for Adult Vaccines by End-Use - Percentage Breakdown of Value Sales for Government Hospitals and Private Healthcare Firms for the Years 2015, 2025 & 2030
  • TABLE 230: Mexico Recent Past, Current & Future Analysis for Adult Vaccines by Vaccine Type - Monovalent Vaccine and Multivalent Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 231: Mexico Historic Review for Adult Vaccines by Vaccine Type - Monovalent Vaccine and Multivalent Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 232: Mexico 15-Year Perspective for Adult Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Monovalent Vaccine and Multivalent Vaccine for the Years 2015, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 233: Rest of Latin America Recent Past, Current & Future Analysis for Adult Vaccines by Technology - Live Attenuated, Inactivated, Subunit, Toxoid, Conjugate and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 234: Rest of Latin America Historic Review for Adult Vaccines by Technology - Live Attenuated, Inactivated, Subunit, Toxoid, Conjugate and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 235: Rest of Latin America 15-Year Perspective for Adult Vaccines by Technology - Percentage Breakdown of Value Sales for Live Attenuated, Inactivated, Subunit, Toxoid, Conjugate and Other Technologies for the Years 2015, 2025 & 2030
  • TABLE 236: Rest of Latin America Recent Past, Current & Future Analysis for Adult Vaccines by End-Use - Government Hospitals and Private Healthcare Firms - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 237: Rest of Latin America Historic Review for Adult Vaccines by End-Use - Government Hospitals and Private Healthcare Firms Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 238: Rest of Latin America 15-Year Perspective for Adult Vaccines by End-Use - Percentage Breakdown of Value Sales for Government Hospitals and Private Healthcare Firms for the Years 2015, 2025 & 2030
  • TABLE 239: Rest of Latin America Recent Past, Current & Future Analysis for Adult Vaccines by Vaccine Type - Monovalent Vaccine and Multivalent Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 240: Rest of Latin America Historic Review for Adult Vaccines by Vaccine Type - Monovalent Vaccine and Multivalent Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 241: Rest of Latin America 15-Year Perspective for Adult Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Monovalent Vaccine and Multivalent Vaccine for the Years 2015, 2025 & 2030
• MIDDLE EAST
  • Adult Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 242: Middle East Recent Past, Current & Future Analysis for Adult Vaccines by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 243: Middle East Historic Review for Adult Vaccines by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 244: Middle East 15-Year Perspective for Adult Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
  • TABLE 245: Middle East Recent Past, Current & Future Analysis for Adult Vaccines by Technology - Live Attenuated, Inactivated, Subunit, Toxoid, Conjugate and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 246: Middle East Historic Review for Adult Vaccines by Technology - Live Attenuated, Inactivated, Subunit, Toxoid, Conjugate and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 247: Middle East 15-Year Perspective for Adult Vaccines by Technology - Percentage Breakdown of Value Sales for Live Attenuated, Inactivated, Subunit, Toxoid, Conjugate and Other Technologies for the Years 2015, 2025 & 2030
  • TABLE 248: Middle East Recent Past, Current & Future Analysis for Adult Vaccines by End-Use - Government Hospitals and Private Healthcare Firms - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 249: Middle East Historic Review for Adult Vaccines by End-Use - Government Hospitals and Private Healthcare Firms Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 250: Middle East 15-Year Perspective for Adult Vaccines by End-Use - Percentage Breakdown of Value Sales for Government Hospitals and Private Healthcare Firms for the Years 2015, 2025 & 2030
  • TABLE 251: Middle East Recent Past, Current & Future Analysis for Adult Vaccines by Vaccine Type - Monovalent Vaccine and Multivalent Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 252: Middle East Historic Review for Adult Vaccines by Vaccine Type - Monovalent Vaccine and Multivalent Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 253: Middle East 15-Year Perspective for Adult Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Monovalent Vaccine and Multivalent Vaccine for the Years 2015, 2025 & 2030
• IRAN
  • TABLE 254: Iran Recent Past, Current & Future Analysis for Adult Vaccines by Technology - Live Attenuated, Inactivated, Subunit, Toxoid, Conjugate and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 255: Iran Historic Review for Adult Vaccines by Technology - Live Attenuated, Inactivated, Subunit, Toxoid, Conjugate and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 256: Iran 15-Year Perspective for Adult Vaccines by Technology - Percentage Breakdown of Value Sales for Live Attenuated, Inactivated, Subunit, Toxoid, Conjugate and Other Technologies for the Years 2015, 2025 & 2030
  • TABLE 257: Iran Recent Past, Current & Future Analysis for Adult Vaccines by End-Use - Government Hospitals and Private Healthcare Firms - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 258: Iran Historic Review for Adult Vaccines by End-Use - Government Hospitals and Private Healthcare Firms Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 259: Iran 15-Year Perspective for Adult Vaccines by End-Use - Percentage Breakdown of Value Sales for Government Hospitals and Private Healthcare Firms for the Years 2015, 2025 & 2030
  • TABLE 260: Iran Recent Past, Current & Future Analysis for Adult Vaccines by Vaccine Type - Monovalent Vaccine and Multivalent Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 261: Iran Historic Review for Adult Vaccines by Vaccine Type - Monovalent Vaccine and Multivalent Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 262: Iran 15-Year Perspective for Adult Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Monovalent Vaccine and Multivalent Vaccine for the Years 2015, 2025 & 2030
• ISRAEL
  • TABLE 263: Israel Recent Past, Current & Future Analysis for Adult Vaccines by Technology - Live Attenuated, Inactivated, Subunit, Toxoid, Conjugate and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 264: Israel Historic Review for Adult Vaccines by Technology - Live Attenuated, Inactivated, Subunit, Toxoid, Conjugate and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 265: Israel 15-Year Perspective for Adult Vaccines by Technology - Percentage Breakdown of Value Sales for Live Attenuated, Inactivated, Subunit, Toxoid, Conjugate and Other Technologies for the Years 2015, 2025 & 2030
  • TABLE 266: Israel Recent Past, Current & Future Analysis for Adult Vaccines by End-Use - Government Hospitals and Private Healthcare Firms - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 267: Israel Historic Review for Adult Vaccines by End-Use - Government Hospitals and Private Healthcare Firms Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 268: Israel 15-Year Perspective for Adult Vaccines by End-Use - Percentage Breakdown of Value Sales for Government Hospitals and Private Healthcare Firms for the Years 2015, 2025 & 2030
  • TABLE 269: Israel Recent Past, Current & Future Analysis for Adult Vaccines by Vaccine Type - Monovalent Vaccine and Multivalent Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 270: Israel Historic Review for Adult Vaccines by Vaccine Type - Monovalent Vaccine and Multivalent Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 271: Israel 15-Year Perspective for Adult Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Monovalent Vaccine and Multivalent Vaccine for the Years 2015, 2025 & 2030
• SAUDI ARABIA
  • TABLE 272: Saudi Arabia Recent Past, Current & Future Analysis for Adult Vaccines by Technology - Live Attenuated, Inactivated, Subunit, Toxoid, Conjugate and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 273: Saudi Arabia Historic Review for Adult Vaccines by Technology - Live Attenuated, Inactivated, Subunit, Toxoid, Conjugate and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 274: Saudi Arabia 15-Year Perspective for Adult Vaccines by Technology - Percentage Breakdown of Value Sales for Live Attenuated, Inactivated, Subunit, Toxoid, Conjugate and Other Technologies for the Years 2015, 2025 & 2030
  • TABLE 275: Saudi Arabia Recent Past, Current & Future Analysis for Adult Vaccines by End-Use - Government Hospitals and Private Healthcare Firms - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 276: Saudi Arabia Historic Review for Adult Vaccines by End-Use - Government Hospitals and Private Healthcare Firms Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 277: Saudi Arabia 15-Year Perspective for Adult Vaccines by End-Use - Percentage Breakdown of Value Sales for Government Hospitals and Private Healthcare Firms for the Years 2015, 2025 & 2030
  • TABLE 278: Saudi Arabia Recent Past, Current & Future Analysis for Adult Vaccines by Vaccine Type - Monovalent Vaccine and Multivalent Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 279: Saudi Arabia Historic Review for Adult Vaccines by Vaccine Type - Monovalent Vaccine and Multivalent Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 280: Saudi Arabia 15-Year Perspective for Adult Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Monovalent Vaccine and Multivalent Vaccine for the Years 2015, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 281: UAE Recent Past, Current & Future Analysis for Adult Vaccines by Technology - Live Attenuated, Inactivated, Subunit, Toxoid, Conjugate and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 282: UAE Historic Review for Adult Vaccines by Technology - Live Attenuated, Inactivated, Subunit, Toxoid, Conjugate and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 283: UAE 15-Year Perspective for Adult Vaccines by Technology - Percentage Breakdown of Value Sales for Live Attenuated, Inactivated, Subunit, Toxoid, Conjugate and Other Technologies for the Years 2015, 2025 & 2030
  • TABLE 284: UAE Recent Past, Current & Future Analysis for Adult Vaccines by End-Use - Government Hospitals and Private Healthcare Firms - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 285: UAE Historic Review for Adult Vaccines by End-Use - Government Hospitals and Private Healthcare Firms Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 286: UAE 15-Year Perspective for Adult Vaccines by End-Use - Percentage Breakdown of Value Sales for Government Hospitals and Private Healthcare Firms for the Years 2015, 2025 & 2030
  • TABLE 287: UAE Recent Past, Current & Future Analysis for Adult Vaccines by Vaccine Type - Monovalent Vaccine and Multivalent Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 288: UAE Historic Review for Adult Vaccines by Vaccine Type - Monovalent Vaccine and Multivalent Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 289: UAE 15-Year Perspective for Adult Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Monovalent Vaccine and Multivalent Vaccine for the Years 2015, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 290: Rest of Middle East Recent Past, Current & Future Analysis for Adult Vaccines by Technology - Live Attenuated, Inactivated, Subunit, Toxoid, Conjugate and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 291: Rest of Middle East Historic Review for Adult Vaccines by Technology - Live Attenuated, Inactivated, Subunit, Toxoid, Conjugate and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 292: Rest of Middle East 15-Year Perspective for Adult Vaccines by Technology - Percentage Breakdown of Value Sales for Live Attenuated, Inactivated, Subunit, Toxoid, Conjugate and Other Technologies for the Years 2015, 2025 & 2030
  • TABLE 293: Rest of Middle East Recent Past, Current & Future Analysis for Adult Vaccines by End-Use - Government Hospitals and Private Healthcare Firms - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 294: Rest of Middle East Historic Review for Adult Vaccines by End-Use - Government Hospitals and Private Healthcare Firms Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 295: Rest of Middle East 15-Year Perspective for Adult Vaccines by End-Use - Percentage Breakdown of Value Sales for Government Hospitals and Private Healthcare Firms for the Years 2015, 2025 & 2030
  • TABLE 296: Rest of Middle East Recent Past, Current & Future Analysis for Adult Vaccines by Vaccine Type - Monovalent Vaccine and Multivalent Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 297: Rest of Middle East Historic Review for Adult Vaccines by Vaccine Type - Monovalent Vaccine and Multivalent Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 298: Rest of Middle East 15-Year Perspective for Adult Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Monovalent Vaccine and Multivalent Vaccine for the Years 2015, 2025 & 2030
• AFRICA
  • Adult Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 299: Africa Recent Past, Current & Future Analysis for Adult Vaccines by Technology - Live Attenuated, Inactivated, Subunit, Toxoid, Conjugate and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 300: Africa Historic Review for Adult Vaccines by Technology - Live Attenuated, Inactivated, Subunit, Toxoid, Conjugate and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 301: Africa 15-Year Perspective for Adult Vaccines by Technology - Percentage Breakdown of Value Sales for Live Attenuated, Inactivated, Subunit, Toxoid, Conjugate and Other Technologies for the Years 2015, 2025 & 2030
  • TABLE 302: Africa Recent Past, Current & Future Analysis for Adult Vaccines by End-Use - Government Hospitals and Private Healthcare Firms - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 303: Africa Historic Review for Adult Vaccines by End-Use - Government Hospitals and Private Healthcare Firms Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 304: Africa 15-Year Perspective for Adult Vaccines by End-Use - Percentage Breakdown of Value Sales for Government Hospitals and Private Healthcare Firms for the Years 2015, 2025 & 2030
  • TABLE 305: Africa Recent Past, Current & Future Analysis for Adult Vaccines by Vaccine Type - Monovalent Vaccine and Multivalent Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 306: Africa Historic Review for Adult Vaccines by Vaccine Type - Monovalent Vaccine and Multivalent Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 307: Africa 15-Year Perspective for Adult Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Monovalent Vaccine and Multivalent Vaccine for the Years 2015, 2025 & 2030

IV. COMPETITION